Acadia Pharmaceuticals Inc. shares tumbled to their lowest level in four years after a CNN report raised questions about whether its lead treatment played a role in the deaths of already sick and elderly patients.
CNN cited an analysis by a nonprofit health-care organization that found 244 deaths involving patients on Nuplazid, which treats hallucinations and psychosis associated with Parkinson’s disease, in the first nine months after its 2016 introduction. The drug was also named in several hundred “adverse events reports” — which include side effects and other issues — to the U.S. Food and Drug Administration, CNN
